NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

As explained above, it has become well recognized that pseudo-progression (PsPD) may occur in a substantial percentage of patients (e.g., up to 30% of brain cancer patients)

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

First answer the simple question: can DCVax-L trigger massive t-cell infiltration? The following is the hint in case you cannot answer the question.

I thought I put everything in English even simple for kids in elementary school. Why do you have the problem to understand it? Did I say for CI to work t-cells have to show up first at tumor site? CSF1R-I can deplete tumor-associated macrophages activated by t-cell infiltration.

You did see that Merck and Daiichi had the collaboration trial on the combination of keytruda with CSF1R-I which was terminated earlier because of lack of efficacy, didn't you?